Next Article in Journal
Life Cycle and Phylogeography of True Truffles
Next Article in Special Issue
Special Issue: “Genomics of Stroke”
Previous Article in Journal
Genome-Wide Analysis in Drosophila Reveals the Genetic Basis of Variation in Age-Specific Physical Performance and Response to ACE Inhibition
Previous Article in Special Issue
The Genetic Landscape of Patent Foramen Ovale: A Systematic Review
 
 
Review

Influence of Haptoglobin Polymorphism on Stroke in Sickle Cell Disease Patients

1
Department of Anesthesiology, Center for Translational Research in Neurodegenerative Disease, University of Florida College of Medicine, Gainesville, FL 32610, USA
2
Department of Biobehavioral Nursing Science, University of Florida College of Nursing, Gainesville, FL 32610, USA
3
Departments of Neurology, Psychiatry, Pharmaceutics, and Neuroscience, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL 32610, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Svetlana A. Limborska and Ivan B. Filippenkov
Genes 2022, 13(1), 144; https://doi.org/10.3390/genes13010144
Received: 1 December 2021 / Revised: 5 January 2022 / Accepted: 7 January 2022 / Published: 14 January 2022
(This article belongs to the Special Issue Genomics of Stroke)
This review outlines the current clinical research investigating how the haptoglobin (Hp) genetic polymorphism and stroke occurrence are implicated in sickle cell disease (SCD) pathophysiology. Hp is a blood serum glycoprotein responsible for binding and removing toxic free hemoglobin from the vasculature. The role of Hp in patients with SCD is critical in combating blood toxicity, inflammation, oxidative stress, and even stroke. Ischemic stroke occurs when a blocked vessel decreases oxygen delivery in the blood to cerebral tissue and is commonly associated with SCD. Due to the malformed red blood cells of sickle hemoglobin S, blockage of blood flow is much more prevalent in patients with SCD. This review is the first to evaluate the role of the Hp polymorphism in the incidence of stroke in patients with SCD. Overall, the data compiled in this review suggest that further studies should be conducted to reveal and evaluate potential clinical advancements for gene therapy and Hp infusions. View Full-Text
Keywords: brain ischemia; genotype; hemolytic anemia; hospitalization; inflammation; mini-stroke; oxidative stress; pain crisis; silent cerebral infarction; therapy; vaso-occlusion brain ischemia; genotype; hemolytic anemia; hospitalization; inflammation; mini-stroke; oxidative stress; pain crisis; silent cerebral infarction; therapy; vaso-occlusion
Show Figures

Figure 1

MDPI and ACS Style

Edwards, O.; Burris, A.; Lua, J.; Wilkie, D.J.; Ezenwa, M.O.; Doré, S. Influence of Haptoglobin Polymorphism on Stroke in Sickle Cell Disease Patients. Genes 2022, 13, 144. https://doi.org/10.3390/genes13010144

AMA Style

Edwards O, Burris A, Lua J, Wilkie DJ, Ezenwa MO, Doré S. Influence of Haptoglobin Polymorphism on Stroke in Sickle Cell Disease Patients. Genes. 2022; 13(1):144. https://doi.org/10.3390/genes13010144

Chicago/Turabian Style

Edwards, Olivia, Alicia Burris, Josh Lua, Diana J. Wilkie, Miriam O. Ezenwa, and Sylvain Doré. 2022. "Influence of Haptoglobin Polymorphism on Stroke in Sickle Cell Disease Patients" Genes 13, no. 1: 144. https://doi.org/10.3390/genes13010144

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop